Quotables
"I watched his countenance closely, to see if he was not deranged ... and I was assured by other senators after he left the room that they had no confidence in it."
U.S. Senator Smith of Indiana ; After seeing Samuel Morse demonstrate the telegraph.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8101174 | Pharmaceutical compositions for treating arthritis and inflammatory disease The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifyin... | 01/24/2012 |
| 7399465 | Pharmaceutical compositions for treating arthritis and inflammatory disease The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifyin... | 07/15/2008 |
| 7364726 | Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary... | 04/29/2008 |
| 7264820 | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokline This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form of primary... | 09/04/2007 |
| 6955894 | Method for producing TNF receptor releasing enzyme The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are method for identifying... | 10/18/2005 |
| 6930084 | Treating arthritis with TNF receptor releasing enzyme The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifyin... | 08/16/2005 |
| 6911314 | Screening for drugs that affect TNF receptor releasing enzyme The biological effects of the cytokine TNF are mediated by binding to receptors on the surface of cells. This disclosure describes new proteins and polynucleotides that promote enzymatic cleavage and release of TNF receptors. Also provided are methods for identifyin... | 06/28/2005 |
| 6858402 | System for discovering and producing polypeptides that cause TNF receptor shedding The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the ca... | 02/22/2005 |
| 6593456 | Tumor necrosis factor receptor releasing enzyme The present invention relates to methods of regulating TNF receptor releasing enzyme (TRRE) activity. Composition altering TRRE activity, including a family of proteins and the genes encoding these proteins having TRRE activity, are provided. These protei... | 07/15/2003 |
| 6573062 | Method for obtaining modulators of TNF receptor releasing enzyme The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated... | 06/03/2003 |
| 6569664 | Native TNF receptor releasing enzyme The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated... | 05/27/2003 |
| 6277368 | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise a source of tumor-associated antigen, and a cytokine-secreting cell line. Tumor antigen may be provided in the form... | 08/21/2001 |
| 6207147 | Cancer immunotherapy using tumor cells combined with mixed lymphocytes This invention comprises cellular vaccines and methods of using them in cancer immunotherapy, particularly in humans. The vaccines comprise stimulated lymphocytes allogeneic to the subject being treated, along with a source of tumor-associated antigen. Th... | 03/27/2001 |
| 6203787 | Treating tumors using implants comprising combinations of allogeneic cells This invention provides methods and compositions for treating tumors by implanting near the tumor an alloactivated cell population. The cell population is made up of a plurality of third-party donor cells that have been cultured together ex vivo, and harv... | 03/20/2001 |
| 6136306 | Method for treating tumors A method is provided for treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate ... | 10/24/2000 |
| 5837233 | Method for treating tumors A method is provided for treatment of a mammalian patient having a tumor by administering to the patient allogenic donor lymphocytes that have been co-cultured in the presence of the patient-derived lymphocytes under conditions sufficient to alloactivate ... | 11/17/1998 |
